Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

GLP-1 prescriptions rise among children under 12 despite FDA age limit

12 September 2026 · By · Wire by Fusion42

Published

12 September 2026

Topic

opportunities

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at wcvb.com →

◆ Verified

Fusion42 · 12 September 2026 · Fusion42 review

There is an increase in GLP-1 drug prescriptions for children under 12 years old even though the FDA has not approved these drugs for that age group in the United States.

This Wire brief sits within Fusion42's coverage of Health, and 3 sources have reported it between 4 Sep 2026 and 12 Sep 2026.

◆ ◆ The Wire takeaway

You face regulatory scrutiny and reputational risk as GLP-1 use expands in children under 12 without FDA approval. Adjust product development or messaging now to address evolving safety and compliance expectations.

◆ Coverage

3 sources · first reported 4 Sep 2026 · latest 12 Sep 2026

◆ Related on Wire

◆ Topics

Healthglp-1pediatric-prescriptionsfda-regulationdrug-safetyhealthcare